嘉实中证医药健康100策略ETF联接C(008155)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
8,616,974.95 |
-23,556,295.12 |
-30,515,698.22 |
-18,181,512.32 |
| 利息合计 |
15,039.99 |
33,476.22 |
17,468.00 |
41,237.97 |
| 其中：存款利息收入 |
15,039.99 |
33,476.22 |
17,468.00 |
41,237.97 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-9,726,905.87 |
-15,497,289.90 |
-7,829,442.90 |
-12,683,813.05 |
| 其中：股票投资收益 |
-67,432.39 |
-641,637.25 |
-521,167.91 |
-827,253.84 |
| 基金投资收益 |
-9,725,269.83 |
-14,958,450.50 |
-7,377,639.51 |
-11,943,030.68 |
| 债券投资收益 |
- |
17.75 |
207.87 |
412.26 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
65,796.35 |
102,780.10 |
69,156.65 |
86,059.21 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
18,312,878.45 |
-8,130,058.97 |
-22,713,457.74 |
-5,570,518.82 |
| 其他收入 |
15,962.38 |
37,577.53 |
9,734.42 |
31,581.58 |
| 费用 |
222,394.49 |
478,919.67 |
252,790.08 |
584,531.99 |
| 管理人报酬 |
30,814.03 |
67,608.74 |
33,611.41 |
78,990.27 |
| 基金托管费 |
6,162.74 |
13,521.71 |
6,722.27 |
15,798.11 |
| 销售服务费 |
114,196.09 |
253,744.27 |
132,396.61 |
328,117.29 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
71,221.63 |
144,044.95 |
80,059.79 |
161,626.32 |
| 利润总额 |
8,394,580.46 |
-24,035,214.79 |
-30,768,488.30 |
-18,766,044.31 |
微信公众号
证券之星APP
基本资料
